RedHill Biopharma Faces Nasdaq Compliance Challenges Ahead of Key Deadlines RedHill Biopharma Ltd. announced its non-compliance with Nasdaq's equity rule, revealing a $4.7 million deficit. The company has options to regain compliance ahead of key deadlines.

RedHill Biopharma Faces Nasdaq Compliance Challenges Ahead of Key Deadlines #Israel #Tel_Aviv #Compliance #RedHill_Biopharma #Nasdaq_RDHL